Hantavirus vaccine in 2026?

Traders currently price "No" at 95% for "Hantavirus vaccine in 2026? ". The market has traded $130K in total volume and resolves Dec 31, 2026. No licensed hantavirus vaccine is expected by December 2026, as reflected in the 94.5% market-implied odds for "No." Most candidates, including DNA vaccines targeting Hantaan, Puumala, and Andes viruses, remain in Phase 1 or early Phase 2 trials, with demonstrated safety and neutralizing antibody responses but no completed Phase 3 efficacy studies. Inactivated vaccines licensed in parts of Asia cover limited strains and lack broad approval in the US or Europe. Standard development and regulatory timelines for rare-disease vaccines make 2026 approval improbable absent major acceleration. Unexpected Phase 3 initiation with rapid enrollment or emergency-use authorization tied to a large outbreak could shift odds, though current pipelines show no such trajectory.

Odds sourced live from Polymarket, refreshed through the day. Prediction-market participation carries risk and may be restricted in your jurisdiction. Informational only — not investment advice.